Hutchison China MediTech - An emerging global biopharma

06:58 EDT 5 Jul 2019 | FinanzNachrichten

Hutchison China MediTech (HCM) has announced positive data that key late-stage asset surufatinib met the primary endpoint of PFS in non-pancreatic at the Phase III interim analysis. This translates...

Original Article: Hutchison China MediTech - An emerging global biopharma


More From BioPortfolio on "Hutchison China MediTech - An emerging global biopharma"

Quick Search

Relevant Topics

Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...